Pharma Commercial & Market Access · Healthcare & Life Sciences
Should you build or buy Pharma Field Reimbursement & Patient Access Hub Platform?
Pharma field reimbursement and patient access hub platforms manage the end-to-end workflow from prescription to therapy initiation, including benefit verification, prior authorization processing, copay and patient assistance program adjudication, and bridge supply coordination. These platforms combine case management software with BPaaS operations — benefits investigators, prior auth coordinators, and case managers — to reduce the time from prescription to first dose.
The build-vs-buy decision for Pharma Field Reimbursement & Patient Access Hub Platform turns on how much a manufacturer can realistically own the workflow configuration and data layer versus how dependent the commercial outcome is on the BPaaS labor infrastructure vendors have built; the calculus is moving as digital prior auth and payer API integrations shift some of the work into software.
Build it, buy it, or bridge?
When building makes sense
Building internal patient access capabilities makes the most sense when a manufacturer has a clear strategy for owning the workflow configuration and patient data layer — not just the brand's copay rules, but the PA escalation logic, adherence outreach sequences, and case-routing criteria that directly shape speed-to-therapy outcomes. The BPaaS core (benefits investigators, prior auth coordinators) isn't a realistic build target, but the software configuration that governs how those workflows run is. Manufacturers with multiple specialty or rare-disease brands can justify the investment in proprietary hub technology when the patient access strategy is genuinely differentiated across brands and when data ownership — particularly patient journey analytics and adherence patterns — is a strategic input into contracting or HEOR strategy. The window for this argument is expanding as digital PA mandates reduce the human coordination burden.
When buying makes sense
Buying a hub platform, including the BPaaS operations, is the right call for most manufacturers because the human infrastructure is not buildable on any reasonable timeline. Vendors like AssistRx, CareMetx, and ConnectiveRx operate programs where the benefits investigators, prior auth coordinators, and case managers are already trained and the payer connections are already active. Speed to patient is a real commercial lever, especially at launch — the difference between five days and three weeks to therapy initiation has measurable volume impact. Manufacturers that treat hub operations as a software-only decision often underestimate how much the BPaaS layer determines outcomes. For early-stage companies and single-brand manufacturers, buying the full service model is the faster and lower-risk path to access.
The desk read
Patient access velocity is a real commercial lever, particularly at launch. The time from prescription to therapy initiation affects both volume and adherence, and vendors like AssistRx, CareMetx, and ConnectiveRx operate hub programs where the BPaaS component, benefits investigators, prior auth coordinators, case managers, is as much the product as the software. That human-in-the-loop infrastructure isn't a build option in any near-term sense.
The more tractable question is how much workflow customization and data ownership a manufacturer retains over the hub vendor relationship. Each brand's copay program rules, PA escalation criteria, and adherence outreach logic reflect commercial strategy specific to that drug and patient population. Manufacturers that treat hub selection as a software buy often find the platform shapes their patient-access workflows more than their own strategy does. The build case concentrates on whether a manufacturer can own the workflow configuration deeply enough to drive the patient-access outcomes that matter commercially, well past replacing the BPaaS core. PHIL and Medmonk serve as alternatives with different pricing and service models.
Frequently asked
What is Pharma Field Reimbursement & Patient Access Hub Platform?
Pharma field reimbursement and patient access hub platforms manage the end-to-end workflow from prescription to therapy initiation, including benefit verification, prior authorization processing, copay and patient assistance program adjudication, and bridge supply coordination. These platforms combine case management software with BPaaS operations — benefits investigators, prior auth coordinators, and case managers — to reduce the time from prescription to first dose.
When does building Pharma Field Reimbursement & Patient Access Hub Platform make sense?
Building internal patient access capabilities is most defensible when a manufacturer wants to own the workflow configuration and patient data layer — the copay rules, PA escalation logic, and adherence outreach criteria — rather than inherit a vendor's defaults. This argument strengthens for manufacturers with multiple specialty brands where access strategy varies meaningfully across the portfolio.
When does buying Pharma Field Reimbursement & Patient Access Hub Platform make sense?
Buying makes sense for most manufacturers because the BPaaS labor infrastructure — benefits investigators, prior auth coordinators, case managers — is not buildable on any reasonable timeline, and vendors already have payer connections active. For launch situations especially, speed to therapy initiation is a direct commercial lever that vendor platforms deliver faster.
What are the main Pharma Field Reimbursement & Patient Access Hub Platform vendors?
Representative vendors include AssistRx (iAssist), ConnectiveRx, CareMetx, PHIL. B4 Pro scores the full set.
How is digital prior authorization changing the hub platform decision?
Federal mandates requiring payers to offer electronic PA processing are automating parts of what was previously manual coordination work, which gradually reduces the BPaaS labor dependency. This shifts more of the hub decision toward the software configuration layer — where manufacturers can own program rules and workflows more practically than they could when the process was primarily human-driven.